[CANCER RESEARCH 53, 5829–5832, December 1, 1993]

Announcements

(Requests for announcements must be received at least 3 months before publication.)

NEW SCHEDULE FOR ANNUAL MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH BEGINNING IN 1994

In May 1992 the Board of Directors of the American Association for Cancer Research voted to hold the AACR Annual Meeting separately from that of the American Society of Clinical Oncology (ASCO). The Board made this decision after careful consideration of the recommendations of the AACR's Task Force on Clinical Investigations. It is felt that an independent annual meeting is essential to the vitally important goal of the AACR to provide more programs of relevance to clinical researchers and to have the AACR Annual Meeting serve as the primary forum for cancer research ranging from the bench to the clinic. The intent of scheduling the meetings consecutively has always been to facilitate interaction and scientific communication among clinical and laboratory scientists. However, the extraordinary recent growth in both meetings hampers that interaction. For a variety of reasons, investigators are unable to attend 7 consecutive days of scientific sessions. As a result, fewer than 20% of the AACR registrants also register for ASCO, and many of those who do register for both meetings attend only 1 day of the AACR meeting. The AACR feels that a separate Annual Meeting will enable more clinical researchers to attend the entire meeting of the AACR.

ASCO will continue to meet in mid-May. Starting in 1994, the AACR Annual Meeting will take place in late March or in April over dates that do not conflict with the FASEB meeting or the Easter and Passover holidays. The AACR meeting will be scheduled over 4 days. Regular scientific sessions will begin on Sunday morning and conclude on Wednesday afternoon to enable registrants to take advantage of airfare discounts requiring Saturday stay-overs.

The 1994 Annual Meeting will take place from Sunday, April 10 through Wednesday, April 13 at the Moscone Center in San Francisco, CA. The deadline for submission of abstracts was **October 25, 1993.** Dates and locations have also been confirmed for the following years:

1995 March 19–22 Toronto, Ontario, Canada
1996 April 21–24 Washington, DC

NEW PRIVILEGES AND RESPONSIBILITIES OF CORRESPONDING MEMBERSHIP

In a ballot distributed in Spring 1993, AACR members approved a number of amendments to the Association's By-Laws. Several of these amendments affect the privileges and responsibilities of corresponding members. Corresponding members may now sponsor candidates for active, corresponding, and associate membership. All corresponding members, regardless of their year of election to the Association, are now required to pay dues. (Previously, dues payment had been voluntary for corresponding members elected before 1985.) If qualified for emeritus membership, corresponding members may now transfer into this category and retain all of their previous membership privileges.

BROADENING OF ASSOCIATE MEMBERSHIP

Also approved in the recent By-Laws Ballot was an amendment broadening associate membership to qualified persons throughout the world. There will be no geographic restrictions. All graduate and medical students, postdoctoral fellows, and physicians-in-training who are following a course of study or who are working in a research program relevant to cancer investigations are now welcome to apply for this category of membership. One active or corresponding member of the Association in good standing must serve as a sponsor for the applicant. Annual dues for associate members are $30 for residents of the Americas, and $40 for those in other countries.

CALL FOR SUGGESTIONS FOR ASSOCIATION OFFICERS AND DIRECTORS

The Nominating Committee will prepare a slate of two AACR members for the office of President-Elect for 1994–95 and a slate of eight AACR members for four seats on the Board of Directors for 1994–97. The Committee intends to construct a slate which reflects the scientific and geographic diversity of the Association, and suggestions from members would be especially valuable in achieving this goal.

Members wishing to suggest candidates for President-Elect or for the Board should submit the name or names to the Association Office. A brief paragraph describing each candidate's qualifications should accompany all suggestions; the Committee will obtain full dossiers for any nominee it wishes to consider more fully. Members' suggestions should arrive in the AACR Office no later than November 5, 1993. Please note that, according to the Association's By-Laws, any person who has previously been elected to a full term on the Board cannot stand for reelection until at least two years have passed since the conclusion of the term of office.

AACR SPECIAL CONFERENCES IN CANCER RESEARCH

A number of meetings are now being organized in the AACR's new series of smaller scientific meetings. The topics, dates, locations, and program committees for these meetings are given on the following page. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 620 Chestnut Street, Suite 816, Philadelphia, PA 19106-3483.

RISK ASSESSMENT IN ENVIRONMENTAL CARCINOGENESIS

(Co-sponsored by the Environmental Mutagen Society)
January 17–22, 1994
(Please note revised date)
Whistler Resort and Conference Center,
Whistler, British Columbia, Canada

Chairpersons
Philip C. Hanawalt, Stanford, CA
James A. Swenberg, Chapel Hill, NC

Program Committee
John Ashby, Macclesfield, England
William H. Farland, Washington, DC
Barry W. Glickman, Sydney, British Columbia, Canada
Carol J. Henry, Sacramento, CA
B. Singer, Berkeley, CA
Thomas R. Skopek, Research Triangle Park, NC
Roger W. Wiseman, Research Triangle Park, NC

Session Topics
Keynote Address: James A. Swenberg
Critical Events in Human Carcinogenesis
Molecular Epidemiology and Biomarkers of Exposure
Markers of Susceptibility and Genetic Predisposition
Mutational Spectra for Environmental Carcinogens
Endogenous Factors
Scientific Basis of Extrapolation
Biologically Based Risk Assessment and Public Policy

MOLECULAR GENETICS OF PROGRESSION AND METASTASIS

January 31–February 5, 1994
Big Sky Resort, Big Sky, MT

Chairperson
Lance A. Liotta, Bethesda, MD

Program Committee
Eric R. Fearon, New Haven, CT
Patricia S. Steeg, Bethesda, MD
William Stetler-Stevenson, Bethesda, MD
Dennis J. Slamon, Los Angeles, CA

Session Topics
Special Lecture: Marc E. Lippman
Colon Cancer
Melanoma
Breast and Ovarian Cancer
Prostate Cancer
Genomic Instability and Repair
Model Systems
Metastasis Suppression
Clinical Approaches to Cancer Progression

CANCER: PERTURBATIONS IN CELL CYCLE CONTROL AND GENOMIC INTEGRITY

(Co-sponsored by the National Cancer Institute of Canada)
February 19–24, 1994
(Please note revised date)
Banff Springs Hotel, Banff, Alberta, Canada

Chairpersons
Thea D. Tlsty, Chapel Hill, NC
Lawrence A. Loeb, Seattle, WA

Program Committee
Philippe Gros, Montreal, Quebec, Canada
Michael Smith, Vancouver, British Columbia, Canada

Session Topics
Keynote Address: Manfred Eigen
Modulators of Growth and Development
Tumor Suppressor Genes
Endogenous Sources of DNA Damage
Responses to DNA Damage
Controls of Genomic Integrity
Genetic Integrity and Carcinogenesis
Cell Cycle
Terminal Arrest

GROWTH FACTORS, DEVELOPMENT, AND CANCER

(Joint Meeting with the Friedrich Miescher-Institut)
March 5–11, 1994
Congress Center, Interlaken, Switzerland

Chairpersons
Harold L. Moses, Nashville, TN
Bernd Groner, Basel, Switzerland

Session Topics
Special Lectures: Harald zur Hausen
Walter Gehring
Positive and Negative Growth Factors and Their Receptors
Receptor-associated Kinases and Phosphatases
Signal Transduction Including Targets for Therapy
Transcription Factors and Homeobox Genes
Tumor Suppressor Genes
Cell-Cell Interactions
Cell-Matrix Interactions and Proteases
Targeted Therapy Including Immunotherapy

TRANSCRIPTIONAL CONTROL OF CELL GROWTH & DIFFERENTIATION

October 16–20, 1994
Chatham Bars Inn, Chatham (Cape Cod), MA

Chairpersons
Eric N. Olson, Houston, TX
Bruce M. Spiegelman, Boston, MA

Session Topics
Cell Cycle and Transcription
Signal Transduction Systems Influencing Transcription
Transcription Factors Controlling Cell Growth
Transcription Factors Controlling Cell Differentiation
Development

MODERN DEVELOPMENTS IN CANCER THERAPEUTICS

(Joint Meeting with Academia Sinica)
November 7–11, 1994
Academia Sinica, Taipei, Taiwan, R.O.C.

Chairperson
Yung-chi Cheng, New Haven, CT

Session Topics
Drug Discovery
Experimental Therapeutics
Drug Resistance
Tumor Biology
Gene Therapy and Vaccines
Novel Therapies
Hepatocellular Carcinogenesis: Treatment and Prevention

BASIC AND CLINICAL ASPECTS OF PROSTATE CANCER

December 8–13, 1994
Marriott's Rancho Las Palmas Resort,
Rancho Mirage (Palm Springs), CA

Chairperson
Donald S. Coffey, Baltimore, MD

MECHANISM OF ACTION OF RETINOIDS, VITAMIN D, AND STEROID HORMONES

January 14–19, 1995
Whistler Resort and Conference Center
Whistler, B.C., Canada

Chairpersons
Michael B. Sporn, Bethesda, MD
Ronald M. Evans, San Diego, CA
David Mangelsdorf, Dallas, TX

MOLECULAR BIOLOGY OF CANCER: IMPLICATIONS FOR PREVENTION AND THERAPY

(Joint Meeting with the Japanese Cancer Association)
February 13–18, 1995
Maui Marriott Hotel, Maui, HI

Chairpersons
Lee W. Wattenberg, Minneapolis, MN
Masaaki Terada, Tokyo, Japan

Session Topics
Differentiation
Signal Transduction
Hormones and Cancer
Multistep Carcinogenesis: Oncogenes and Tumor Suppressor Genes
Genetic Intervention: Antisense and Gene Therapy

CALENDAR OF EVENTS

Uro-Oncology Update: 1994, January 8, 1994, Ritz-Carlton Hotel, Boston, MA. Credits: 4. Contact: Amy Gallagher, Department of Continuing Medical Education, 80 East Concord Street, Boston, MA 02118-2394. Telephone: (617) 638-4605.

Novel Vaccine Strategies, February 23–25, 1994, The Washington Hilton and Towers, Washington, DC. Contact: IBC USA Conferences Inc., 225 Turnpike Road, Southborough, MA 01772-1749. Telephone: (508) 481-6400; FAX: (508) 481-7911.

Cancer and Pregnancy: Medical, Legal & Ethical Dilemmas, March 19, 1994, R. Lee Clark Clinic Conference Center, Houston, TX. Contact: Jeff Rasco, 1515 Holcombe Boulevard, Houston, TX 77030. Telephone: (713) 792-2222.

First International Conference on Germ Cell Tumors, April 16–17, 1994, Palazzo Mauro De Andre, Ravenna, Italy. Contact: Dr. Nadia Colaiuda, Augustea, s.r.l., Via di Roma 86, 48100 Ravenna, Italy. Telephone: 0544/33259-30329; FAX: 0544/34064.

The Clinical Research Meeting, April 29–May 2, 1994, Baltimore Convention Center, Baltimore, MD. Contact: Registration Manager, c/o SLACK, Incorporated, 6900 Grove Road, Thorofare, NJ 08086. Telephone: (609) 848-1000; FAX: (609) 848-5274.

Houston Society of Clinical Pathologists Annual Meeting, Prostatic Diseases, April 30, 1994. JW Marriott Hotel, Houston, TX. Contact: Shirley Roy, 1515 Holcombe Boulevard, Houston, TX 77030. Telephone: (713) 792-2222.

Cell Differentiation and Death, May 1–4, 1994, Ettore, Majorana Centre for Scientific Culture, Erice, Sicily. Contact: Prof. L. Massimo and Dr. G. P. Tonini, Dept. of Paediatric Haematology and Oncology and Laboratory of Oncology, G. Gaslini Children's Hospital, L.go G. Gaslini, 161148 Genova, Italy. Telephone: 0039-10-5636331/227; FAX: 0039-10-3996590.

International Conference on Bioreductive Drug Activation, August 16–19, 1994, Granlibakken Conference Center at Lake Tahoe, Tahoe City, CA. Contact: Dr. Chris A. Pritsos, University of Nevada, Mail Stop 142, Reno, NV. Telephone: (702) 784-6443; FAX: (702) 784-6449.

Fourth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer, September 8–11, 1994, Hyatt Regency Crystal City, Arlington, VA. Contact: Ruth C. Enquist, 1503 - 15th Street. N.E., Rochester, MN 55906. Telephone: (507) 285-1523; FAX: (507) 281-8328.

Forty-seventh Annual Research Symposium on Fundamental Cancer Research, Development, Cell Death, and Cancer, October 11–14, 1994, JW Marriott Hotel, Houston, TX. Contact: Shirley Roy, 1515 Holcombe Boulevard, Houston, TX 77030. Telephone: (713) 792-2222.

Sixteenth Annual Pharmacy Symposium on Cancer Chemotherapy, October 16–18, 1994, JW Marriot Hotel, Houston, TX. Contact: Carol Harreld, Box 131, 1515 Holcombe Boulevard, Houston, TX 77030. Telephone: (713) 792-2222.

Seventeenth Annual Pharmacy Symposium on Cancer Chemotherapy, October 8–10, 1995, JW Marriott Hotel, Houston, TX. Contact: Carol Harreld, Box 131, 1515 Holcombe Boulevard, Houston, TX 77070. Telephone: (713) 792-2222.

Errata

In the article by Stearns *et al.*, which appeared in the July 1, 1993 issue of *Cancer Research* (pp. 3073–3077), measurements of the retinoic acid levels in tumor tissue were incorrect. HPLC measurements have revealed that following liarozole treatment of SCID mice (40 mg/kg for 2 h), tumor tissue extracts contained elevated retinoic acid levels (*i.e.*, 3.9, 5.4, 5.9, 5.1, 6.1 ng/g tissue) in five different s.c. grown PC-3 ML tumors. Four untreated control animals exhibited tumor levels of retinoic acid which fell below the detection limit of 2 ng/g tumor. The data support the original observations but the absolute levels of retinoic acid expressed per gram wet tumor tissue are much lower than the values originally reported (pp. 3075, 3076).

References for HPLC methods

1. McPhillips, D. M., Kalin, J. R., and Hill, D. L. The pharmacokinetics of all-*trans*-retinoic acid and *N*-(2-hydroxyethyl)retinamide in mice as determined with a sensitive and convenient procedure. Drug Metab. Dispos., *15:* 207–211, 1987.
2. Gubler, M. L., and Sherman, M. I. Metabolism of retinoids by embryonal carcinoma cell. J. Biol. Chem., *260:* 9552–9558, 1985.

An error has been found in the article by Akimoto, *et al.*, in the October 1, 1993, issue of *Cancer Research* (pp. 4658–4664). In the "Discussion" section (p. 4663), the following statements are incorrect: "When cardiac cultures were treated with 10 mg/ml (17 μM) doxorubicin for 2 h, cardiac-muscle cells accumulated doxorubicin more than cocultured nonmuscle fibroblasts. However, if these cultures were cotreated with 10 mg/ml (20 μM) verapamil, there was a significant increase of drug fluorescence in the fibroblasts but not in the muscle cells." In both of these statements, "10 mg/ml" should read **"10 μg/ml."**